



Pharmacological Treatment for Psychotic Disorders in Old Age

Guest Editors:

Dr. Alexandre González-Rodríguez

Department of Mental Health.
Parc Tauli University Hospital.
Autonomous University of
Barcelona (UAB). Sabadell,
Barcelona, Spain

agonzalezro@tauli.cat

Prof. Dr. Manuel A. Franco-Martin

1. Department of Psychiatry and
Mental Health, Rio Hortega
University Hospital and Complejo
Asistencial de Zamora, Spain
2. Research Biomedicine Institute
of Salamanca (IBSAL),
Psychosciences research Group
(NEUR08), Salamanca University,
Spain

mfrancom@
saludcastillayleon.es

Deadline for manuscript
submissions:

31 August 2021

Message from the Guest Editors

Dear Colleagues,

Current research shows that elderly patients are at high risk for the development of psychotic symptoms. Several diagnostic categories can be associated with the presence of psychotic symptoms. This is the case for schizophrenia, delusional disorder, mood disorders, dementia, delirium, substance-use disorders, and other medical or neurologic conditions.

The recent literature shows that the efficacy of antipsychotic medications has been confined to the reduction of delusions and hallucinations, and to the diminishing of behavioral disturbances. Age alters the kinetics and dynamics of psychotropic medications, and drugs other than antipsychotics are being tested to treat cognitive, affective, and negative psychotic symptoms.

Knowledge of drug–drug interactions and comorbidities are of special interest for clinicians, as they contribute to higher mortality rates in older psychotic populations. The unmet needs of older patients must be assessed by a comprehensive history and accurate physical and mental health examinations. Adverse events should be checked and worked up, and polypharmacy should be avoided if possible.





International Journal of *Environmental Research and Public Health*

IMPACT
FACTOR
2.849

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Paul B. Tchounwou

Department of Biology, College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, Box 18750, Jackson, MS 39217, USA

Message from the Editor-in-Chief

Addressing the environmental and public health challenges requires engagement and collaboration among clinicians and public health researchers. Discovery and advances in this research field play a critical role in providing a scientific basis for decision-making toward control and prevention of human diseases, especially the illnesses that are induced from environmental exposure to health hazards. *IJERPH* provides a forum for discussion of discoveries and knowledge in these multidisciplinary fields. Please consider publishing your research in this high quality, peer-reviewed, open access journal.

Author Benefits

Open Access:—free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed by the Science Citation Index Expanded (Web of Science), Social Sciences Citation Index (Web of Science), MEDLINE (PubMed), Scopus (Elsevier) and other databases. Full-text available in PubMed Central.

Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2020).

Contact Us

*International Journal of
Environmental Research and Public
Health*

MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/ijerph
ijerph@mdpi.com
@IJERPH_MDPI